Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAXIS phase 2 trial of pacritinib in VEXAS syndrome
jRCT2031250172Phase 2Recruiting
- Sponsor
- Sobi
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in VEXAS syndrome (VEXAS) comparing Pacritinib 200 mg BID, Pacritinib 100 mg BID + placebo and Placebo BID (3 arms). Primary endpoint: Overall Clinical Response (OCR). Started Jul 2025; status: recruiting.
02
Drugs
pacritinib
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on jRCT2031250172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250172.